Christine Lee, MD
Medical Microbiologist and Researcher, Island Health
Clinical Professor, Department of Pathology and Laboratory Medicine, UBC Faculty of Medicine
Dr. Lee is a Clinical Professor in the Department of Pathology and Laboratory Medicine at UBC’s Faculty of Medicine, and works as a researcher and medical microbiologist with Island Health. Trained in Internal Medicine, Infectious Diseases and Medical Microbiology at the University of Toronto, her clinical and research interests include refractory and recurrent Clostridium difficile infection, antimicrobial resistant organisms, inflammatory bowel disease, and fostering appropriate lab use and best practices.
Dr. Lee’s research interests include fecal microbiota transplant, refractory and recurrent Clostridium difficile infection, antimicrobial resistant organisms, inflammatory bowel disease, and fostering appropriate lab use and best practices. Dr. Lee is a recipient of the Michael Smith Foundation for Health Research Health Professional Investigator Award. With this award, she has established the British Columbia Associated Lyophilized (LYO) Microbiota Program (BCaLM), which aims to establish the safety of lyophilized Fecal Microbiota Transplant for patients living with chronic gut disorders.
Selected Publications and Presentations
- Harris, Cailin & Kim, Peter & Waterhouse, Dawn & Feng, Zeny & Niergarth, Jessmyn & Lee, Christine. (2020). Precision medicine and gut dysbiosis. Healthcare Management Forum. 33. 084047041989942. 10.1177/0840470419899426.
- Lee, Christine & Chai, Jocelyn & Hammond, Keely & Jeon, Seong & Patel, Yogita & Goldeh, Christiana & Kim, Peter. (2019). Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure. European Journal of Clinical Microbiology. 38. 1731-1735. 10.1007/s10096-019-03602-2.
- Jeon, Seong & Chai, Jocelyn & Kim, Christiana & Lee, Christine. (2018). Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation. Current Infectious Disease Reports. 20. 10.1007/s11908-018-0627-8.
- Chai, Jocelyn & Lee, Christine. (2018). Management of Primary and Recurrent Clostridium difficile Infection: An Update. Antibiotics. 7. 54. 10.3390/antibiotics7030054.
- Dubberke, Erik & Lee, Christine & Orenstein, Robert & Khanna, Sahil & Hecht, Gail & Gerding, Dale. (2018). Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 67. 10.1093/cid/ciy259.
For a full list of publications, see Dr. Lee’s profile on ResearchGate.
- BCaLM research program: A safe & effective lyophilized fecal microbiota transplantation program for chronic gut disorders Health Professional Investigator Award ($450,000), Michael Smith Foundation for Health Research (2017-2022)
- Digital storytelling: Bringing evidence-based treatment for C. difficile infection closer to home; REACH Award, Michael Smith Foundation for Health Research ($10,000) (2018)
- Improving Treatment Outcomes and Value for Recurrent Clostridium difficile Infection through a Platform Adaptive Trial; Operating Grant: SPOR iCT Rewarding Success - Development Grants ($100,000), Canadian Institutes of Health Research (2018)
- A randomized double-blind, placebo-controlled trial of fecal microbiota transplantation for the induction of remission in adults with active ulcerative colitis, Grants-in-Aid of Research and Innovations in Inflammatory Bowel Disease ($375,000); Crohn’s and Colitis Canada (2018-2021)